News (167)

Transcript : NovoCure Limited, Q1 2024 Earnings Call, May 02, 2024
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 BU
NovoCure : Corporate responsibility report PU
Novocure - METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer AQ
Transcript : NovoCure Limited - Special Call
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer BU
Transcript : NovoCure Limited, Q4 2023 Earnings Call, Feb 22, 2024
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update BU
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer BU
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma BU
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer BU
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability BU
Transcript : NovoCure Limited, Q3 2023 Earnings Call, Oct 26, 2023
Novocure Reports Third Quarter 2023 Financial Results BU
Transcript : NovoCure Limited, Q2 2023 Earnings Call, Jul 27, 2023
Novocure Reports Second Quarter 2023 Financial Results BU
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer AQ
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer BU
Transcript : NovoCure Limited, Q1 2023 Earnings Call, May 04, 2023
NovoCure : Enrollment of phase 3 METIS clinical trial completed, the fourth phase 3 clinical trial to complete enrollment in last 18 months - Form 8-K PU
Novocure Reports First Quarter 2023 Financial Results BU
NovoCure : 2022 environmental, social & governance report PU
Novocure Announces Reimbursement of Optune for the Treatment of Newly Diagnosed Glioblastoma in France AQ
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France BU
NovoCure : Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary overall survival endpoint - Form 8-K PU
Transcript : NovoCure Limited, Q4 2022 Earnings Call, Feb 23, 2023
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update BU
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer BU
Novocure Announces Organizational Changes to Prepare for Future Growth BU
Transcript : NovoCure Limited, Q3 2022 Earnings Call, Oct 27, 2022
Novocure Reports Third Quarter 2022 Financial Results BU
Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business BU
Transcript : NovoCure Limited, Q2 2022 Earnings Call, Jul 28, 2022
NovoCure : Quarterly net revenues of $140.9 million, a 6% increase year-over-year - Form 8-K PU
Novocure Reports Second Quarter 2022 Financial Results BU
NOVOCURE LTD : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K) AQ
NovoCure : Press Release of NovoCure Limited, dated June 3, 2022 - Form 8-K PU
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer BU
Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer GL
Transcript : NovoCure Limited, Q1 2022 Earnings Call, Apr 28, 2022
NovoCure : Quarterly net revenues of $137.5 million with 80% gross margin - Form 8-K PU
Novocure Reports First Quarter 2022 Financial Results BU
Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation BU
Novocure’s General Counsel Resigns After 10 Years of Service BU
Transcript : NovoCure Limited, Q4 2021 Earnings Call, Feb 24, 2022
1234NextSee all

Insiders

Picture Asaf Danziger
Asaf Danziger

Currently, Asaf Danziger occupies the position of Chief Executive Officer & Director at NovoCure Ltd. and Co-Managing Director at NovoCure GmbH (a subsidiary of NovoCure Ltd.). In the past Mr. Danziger occupied the position of Chief Executive Officer of Cybro Medical Ltd. and Communications & Electronics Officer at Israel Defense Forces. He received an undergraduate degree from Ben-Gurion University of the Negev.


Picture Asaf Asaf
Asaf Asaf

Mr. Asaf Asaf is Chief Technology Officer at Karamba Security Ltd and a Principal at Meitar Liquornik Geva & Leshem Brandwein.


Picture Eric Danziger
Eric Danziger

Eric Danziger is the founder of Genability, Inc. He previously worked as an Associate at GulfStar Group, Inc.




Picture Sheldon H. Danziger
Sheldon H. Danziger

Dr. Sheldon H.
Danziger
is President at Russell Sage Foundation.
Dr. Danziger received his BA in Economics, Magna Cum Laude, from Columbia University and PhD in Economics from the Massachusetts Institute of Technology.


Picture Gil Danziger
Gil Danziger

Gil Danziger worked as the Chief Technology Officer at ME mobile GmbH.
Prior to that, he obtained an undergraduate degree from Tel-Aviv University.



Picture Matthew Danziger
Matthew Danziger

Matthew Danziger worked as an Accountant at State Street Corp.
He then worked as a Research Associate at JMP Securities LLC for a year.
After that, he worked as an Associate at Sun Valley Gold LLC and as a Compliance Officer at Matthes Capital Management LLC.
Finally, he worked as an Investor Relations Contact at Pure Storage, Inc. Mr. Danziger completed his undergraduate degree at Colby College.


No results for this search